The R-evolution in non- Hodgkin’s lymphoma therapy
A survey of treatment advances
including rituximab added to
chemotherapy, use of
radiolabelled monoclonal
antibodies and new transplant approaches
Douglas A. Stewart, MD, FRCPC

Essential reading: research
updates and commentaries
Review of important clinical
trial data originally presented
at the 27th Annual San Antonio
Breast Cancer Symposium

GENETIC TOOLS TO PREDICT
DISEASE SEVERITY AND RESPONSE
TO TREATMENT
With commentary by Joseph Ragaz, MD, FRCSC

Professional meetings roster
Your calendar dates for essential
conferences and symposia